Moderna Inc is trading 4.9% up now at $51.46 as investors continue to re-rate the stock following its recent first-quarter update and reiterated 2026 growth framework.
- The company's Q1 results highlighted stronger international vaccine deliveries and multiple late-stage pipeline milestones.
- Positive sentiment is being driven by recent analyst price-target increases and an ongoing 2026 rebound that has seen the stock rise strongly year-to-date.